We are creating some awesome events for you. Kindly bear with us.

Pushing HK as a Regional Hub for the Microbiome Industry

Image Credits: CU Medicine

The Faculty of Medicine of The Chinese University of Hong Kong (CU Medicine), Microbiota I-Center (MagIC), and Hong Kong Science and Technology Parks Corporation (HKSTP) partnered to hold the Microbiome Summit 2023 (the Summit) at Hong Kong Science Park recently.

Over 20 highly-respected international academics and pharmaceutical industry partners discussed the uses of gut microbiome and highlighted the potential for Hong Kong to become a hub for “microbiome industry” innovation and technology in the Asia-Pacific region.

The human gut is often referred to as the “second brain” because it contains more neurons than the spinal cord. The neurotransmitters produced by gut bacteria play a significant role in not only digestion but also various health conditions such as immunity, allergies, obesity, colon cancer, autism, depression, and dementia.

Recent advancements in biotechnology have led to the successful use of gut microbiomes in various important clinical conditions. For instance, the US Food and Drug Administration (FDA) has approved the use of an oral formulation of gut microbiome for the treatment of Clostridium difficile infection, a recurrent and potentially fatal condition.

At CUHK, the first-ever diagnostic test for early colorectal cancer and recurrent colorectal adenomas based on microbiome has been commercialised. CUHK envisions that with advancements in biotechnology, it will be possible to isolate next-generation probiotic bacteria with specific health benefits for the treatment of conditions such as colorectal cancer, diabetes, obesity, autism, and dementia.

CU Medicine innovates clinical applications of gut microbiome

CU Medicine is a global leader in gut microbiome research. The Microbiota I-Centre (MagIC) is an international centre of excellence located in the Hong Kong Science Park, working closely with the Hong Kong Science and Technology Parks Corporation (HKSTP) and its biomedical ecosystem to advance relevant translational research.

CU Medicine is the only faecal microbiota transplantation (FMT) centre in Asia that has received recognition from the United Kingdom. It has already performed a high volume of FMTs which is equivalent to one-third of all FMTs performed in Europe. Over the last twenty years, CUHK Medicine has developed several non-invasive diagnostic cancer tests that have been approved by the National Medical Products Administration (NMPA) for use on the mainland.

Other non-invasive diagnostic tests in the research team’s pipeline include autism, long-covid and Crohn’s disease. Since 2019, the team has established a network of hospitals in Mainland China to collect the world’s largest cohort of 100,000 maternal and foetal samples to enable a better understanding of how early-life gut microbiome influences health outcomes.

Developing HK into a regional hub for the microbiome industry

The Dean of CU Medicine stated that Hong Kong is well-positioned to become a regional hub for the microbiome industry, with its world-class researchers, advanced technology, and strong intellectual property protection. The microbiome market is expected to experience a compound annual growth rate (CAGR) of 30-40% per year.

The government is urged to simplify the regulatory approval process for innovations in the Greater Bay Area. Specifically, it was suggested that a regional office of the National Medical Products Administration (NMPA) be created to accelerate the approval of innovations for use in the Greater Bay Area. This is expected to be an effective way to attract pharmaceutical companies and talent, and help Hong Kong become a new hub for pharmaceutical innovation.

The HKSAR government recently released the ‘Hong Kong Innovation and Technology Development Blueprint’, which proposes strategies in terms of land, talent, and capital. It advocates the establishment a modern version of ‘Noah’s Ark’ to process and store gut microbiome biosamples in the Loop Area.

The CEO of HKSTP stated that the Park has been partnering with stakeholders from the government, industry, academic and research sectors to provide I&T talents with comprehensive ecosystem support for translational research in the healthcare landscape, from bench to bedside, to benefit society.

Over the past five years, the number of biomedical companies in Science Park has grown from 50 to approximately 180, reflecting the continued strong growth of the biomedical technology sector.

The 14th Five-Year Plan and the HKSAR Government’s Hong Kong Innovation and Technology Development Blueprint will help more I&T enterprises “go global” and solidify Hong Kong’s role as a bridge connecting mainland China and the world.


Qlik’s vision is a data-literate world, where everyone can use data and analytics to improve decision-making and solve their most challenging problems. A private company, Qlik offers real-time data integration and analytics solutions, powered by Qlik Cloud, to close the gaps between data, insights and action. By transforming data into Active Intelligence, businesses can drive better decisions, improve revenue and profitability, and optimize customer relationships. Qlik serves more than 38,000 active customers in over 100 countries.


CTC Global Singapore, a premier end-to-end IT solutions provider, is a fully owned subsidiary of ITOCHU Techno-Solutions Corporation (CTC) and ITOCHU Corporation.

Since 1972, CTC has established itself as one of the country’s top IT solutions providers. With 50 years of experience, headed by an experienced management team and staffed by over 200 qualified IT professionals, we support organizations with integrated IT solutions expertise in Autonomous IT, Cyber Security, Digital Transformation, Enterprise Cloud Infrastructure, Workplace Modernization and Professional Services.

Well-known for our strengths in system integration and consultation, CTC Global proves to be the preferred IT outsourcing destination for organizations all over Singapore today.


Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions creates an organizational focus on the strategic outcomes that matter and empowers teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,300 employees supporting 4,500 customers and 2.6 million users worldwide. For more information, visit www.planview.com.


SIRIM is a premier industrial research and technology organisation in Malaysia, wholly-owned by the Minister​ of Finance Incorporated. With over forty years of experience and expertise, SIRIM is mandated as the machinery for research and technology development, and the national champion of quality. SIRIM has always played a major role in the development of the country’s private sector. By tapping into our expertise and knowledge base, we focus on developing new technologies and improvements in the manufacturing, technology and services sectors. We nurture Small Medium Enterprises (SME) growth with solutions for technology penetration and upgrading, making it an ideal technology partner for SMEs.


HashiCorp provides infrastructure automation software for multi-cloud environments, enabling enterprises to unlock a common cloud operating model to provision, secure, connect, and run any application on any infrastructure. HashiCorp tools allow organizations to deliver applications faster by helping enterprises transition from manual processes and ITIL practices to self-service automation and DevOps practices. 


IBM is a leading global hybrid cloud and AI, and business services provider. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Nearly 3,000 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and business services deliver open and flexible options to our clients. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity and service.

Send this to a friend